BCD-261 / Biocad - LARVOL DELTA

Another drug for Crohn’s disease treatment is being developed in Russia (GxP News) - "'A molecule discovered earlier and enzymes synthesized based on it through biotechnological means have shown potential effectiveness in several areas.'...According to Tekutyeva, preclinical trials of the enzyme-based drug are now underway...According to the company’s website, patients are currently being recruited for Phase II...Eligible patients are those 18-75 for whom prior therapies—glucocorticoids, immunosuppressants, or biologics—have proven ineffective. The study will take place in 33 hospitals across 17 Russian cities."

Preclinical • Trial status • Crohn's disease

ULTRAMARINE: A Randomized Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=198 | Recruiting | Sponsor: Biocad

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

COMANDOR: Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - P2 | N=204 | Recruiting | Sponsor: Biocad

New P2 trial • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease